The downstream consequences of calcineurin inhibition.
Batiuk
T D
TD
Halloran
P F
PF
D000001:Calcimycin / Q000494:pharmacology; D019703:Calcineurin; D002148:Calmodulin-Binding Proteins / Q000037:antagonists & inhibitors*; D002478:Cells, Cultured; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D004655:Emulsions; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D012016:Reference Values
D002148:Calmodulin-Binding Proteins; D016207:Cytokines; D004655:Emulsions; D007166:Immunosuppressive Agents; D000001:Calcimycin; D016572:Cyclosporine; D019703:Calcineurin; D010749:Phosphoprotein Phosphatases